Literature DB >> 15586571

Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog.

Rosario Preziosi1, Maria Morini, Giuseppe Sarli.   

Abstract

Thirty-one canine cutaneous masses, diagnosed as mast cell tumors (MCT) by histopathologic analysis, were used to evaluate the immunohistochemical pattern of expression of KIT protein (CD117), a type III tyrosine kinase protein involved in mast cell growth and differentiation. Lesions were graded as I (well differentiated), II (intermediate differentiation), or III (poorly differentiated) according to the following morphologic features: invasiveness, cellularity and cellular morphology, mitotic index, and stromal reaction. Immunohistochemical KIT expression was compared with histologic grade and some histomorphologic features (cell differentiation and nuclear grade) evaluated separately. A possible predictive role of biologic behavior in MCTs for KIT expression was also investigated. Immunohistochemical analysis revealed three different patterns of KIT expression: a cytoplasmic diffuse pattern, a membranous pattern with immunostaining located on the cell surface, and a cytoplasmic perinuclear pattern, where KIT expression was detected in the cytoplasm of the neoplastic mast cells, close to the nucleus. Statistical analysis showed a close relationship between different KIT immunohistochemical patterns and histologic grade (P < 0.00000), cell differentiation (P < 0.00000), and nuclear grade (P < 0.0024). According to Kaplan-Meier-estimated survival curves compared by survival analysis, KIT expression was significantly associated with survival time (P = 0.037) but not cancer-free interval (P = 0.50). Similar to other well-known histomorphological features, KIT expression is a useful parameter of malignancy in cutaneous MCTs. KIT expression also predicted the biological behavior of the tumors in this study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15586571     DOI: 10.1177/104063870401600610

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  9 in total

1.  The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors.

Authors:  Joshua D Webster; Vilma Yuzbasiyan-Gurkan; John B Kaneene; RoseAnn Miller; James H Resau; Matti Kiupel
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

2.  Intranasal mast cell tumor in the dog: A case series.

Authors:  Alison Khoo; Amy Lane; Ken Wyatt
Journal:  Can Vet J       Date:  2017-08       Impact factor: 1.008

3.  Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.

Authors:  Joshua D Webster; Matti Kiupel; Vilma Yuzbasiyan-Gurkan
Journal:  BMC Cancer       Date:  2006-04-01       Impact factor: 4.430

4.  Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study).

Authors:  Galina V Ilyinskaya; Elena V Mukhina; Alesya V Soboleva; Olga V Matveeva; Peter M Chumakov
Journal:  Front Vet Sci       Date:  2018-06-04

5.  The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.

Authors:  Fabio Gentilini; Maria Elena Turba; Claire Dally; Masamine Takanosu; Sena Kurita; Makoto Bonkobara
Journal:  BMC Vet Res       Date:  2020-02-19       Impact factor: 2.741

Review 6.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

7.  Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone.

Authors:  Thais Rodrigues Macedo; Genilson Fernandes de Queiroz; Thaís Andrade Costa Casagrande; Pâmela Almeida Alexandre; Paulo Eduardo Brandão; Heidge Fukumasu; Samanta Rios Melo; Maria Lucia Zaidan Dagli; Ana Carolina B C Fonseca Pinto; Julia Maria Matera
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

8.  The Relevance of CD117-Immunocytochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells.

Authors:  A Sailasuta; D Ketpun; P Piyaviriyakul; S Theerawatanasirikul; P Theewasutrakul; A Rungsipipat
Journal:  Vet Med Int       Date:  2014-02-18

Review 9.  Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal.

Authors:  Michael Willmann; Vilma Yuzbasiyan-Gurkan; Laura Marconato; Mauro Dacasto; Emir Hadzijusufovic; Olivier Hermine; Irina Sadovnik; Susanne Gamperl; Mathias Schneeweiss-Gleixner; Karoline V Gleixner; Thomas Böhm; Barbara Peter; Gregor Eisenwort; Richard Moriggl; Zhixiong Li; Mohamad Jawhar; Karl Sotlar; Erika Jensen-Jarolim; Veronika Sexl; Hans-Peter Horny; Stephen J Galli; Michel Arock; David M Vail; Matti Kiupel; Peter Valent
Journal:  Front Vet Sci       Date:  2021-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.